Skip to main content

Table 1 Effect of cisplatin (CP) and different treatments of AHE on lipid profile

From: Modulatory influence of Acacia hydaspica R. Parker ethyl acetate extract against cisplatin inveigled hepatic injury and dyslipidemia in rats

Group Total cholesterol (mg/dl) HDL (mg/dl) LDL (mg/dl) Triglycerides (mg/dl)
Control 76.50 ± 0.29 b 25.17 ± 0.44b 48.62 ± 0.23b 70.50 ± 1.04b
CP 95.63 ± 0.32 a 20.30 ± 0.36a 165.4 ± 0.32a 92.83 ± 0.60a
AHE alone 76.13 ± 0.19 b 25.33 ± 0.33b 48.57 ± 0.20b 70.33 ± 0.67b
CP + AHE 90.33 ± 0.33 a, b, d 20.83 ± 0.44a, d** 144.0 ± 0.58a, b 84.67 ± 0.67a, b, d
AHE + CP 79.83 ± 0.44 a, b, c 24.03 ± 0.15b, c** 59.67 ± 0.33a, b 76.30 ± 0.35a, b, c
CP + Sily 78.67 ± 0.33 a**, b 24.17 ± 0.61b 58.43 ± 0.22a, b 73.50 ± 0.50b
  1. Values expressed as mean ± SEM
  2. a Significance at p < 0.0001 Vs. control group
  3. b Significance at p < 0.0001 Vs. Cisplatin (CP) group
  4. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
  5. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
  6. ** Significant difference p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests). Sily; Silymarin